Physician profile
Alla Yeras
NPI 1467524603
$1,422.08
in general payments reported to CMS, 2019-2025
11 companies · $159 in 2025
The $159 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $416 · 2020: $34.98 · 2021: $78.62 · 2022: $468 · 2023: $211 · 2024: $54.48 · 2025: $159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $424.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $424.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $328.61 | 2019-2022 | |
| Amgen INC. | $225.33 | 2019-2022 | |
| Genentech USA, INC. | $207.61 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $122.85 | 2023 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $121.35 | 2025 | Austedo Xr |
| Astrazeneca Pharmaceuticals Lp | $107.10 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $100.88 | 2022 | |
| Abbvie INC. | $88.32 | 2023 | Vraylar |
| Pfizer INC. | $74.18 | 2024-2025 | |
| Inari Medical, INC. | $28.11 | 2022 | |
| Gilead Sciences, INC. | $17.74 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alla Yeras listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.